Plus Therapeutics Inc (OQ:PSTV)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4200 Marathon Blvd Ste 200
AUSTIN TX 78756-3433
Tel: N/A
Website: www.plustherapeutics.com
IR: See website
<
Key People
Marc H. Hedrick
President, Chief Executive Officer, Director
Andrew Sims
Chief Financial Officer
Norman D. LaFrance
Chief Medical Officer
Business Overview
Plus Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company's lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi's sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.
Financial Overview
For the nine months ended 30 September 2021, PlusTherapeutics Inc revenues decreased from $303K to $0K. Netloss increased 99% to $9.2M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsChange in fair value of warrants decrease of 100% to $4K(income), Research and development - Gross increase from$1.6M to $3.7M (expense).
Employees: 12 as of Dec 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $6.01M as of Sep 30, 2021
Annual revenue (TTM): $0.00M as of Sep 30, 2021
EBITDA (TTM): -$11.57M as of Sep 30, 2021
Net annual income (TTM): -$12.83M as of Sep 30, 2021
Free cash flow (TTM): -$11.07M as of Sep 30, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 21,175,025 as of Jan 13, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.